

Eisai supports access to treatments for dementia, Alzheimer's in Thailand

08 November 2022 | News

Older age is the most important risk factor for dementia, with prevalence increasing exponentially after the age of 65



Japan-based pharmaceutical firm Eisai Co. has announced that its Thai sales subsidiary Eisai (Thailand) Marketing Co. has made an agreement to collaborate in supporting access to treatments for dementia, including Alzheimer's disease, in Thailand with Thai Life Insurance Public Company.

In Thailand, the number of people suffering from dementia is expected to increase significantly from the current 600 thousand to 1.1 million by 2030 due to the rapid aging of the population, and the financial burden of the people suffering from dementia, including Alzheimer's disease, and their families due to care is also expected to increase.

With this agreement, Eisai Thailand, together with Thai Life Insurance, which has expertise in the design and development of life and medical insurance products, will work together to design insurance products to cover dementia, including Alzheimer's disease raise awareness of the disease, and build a dementia ecosystem to secure access to next-generation Alzheimer's disease treatments in Thailand.